Dual-Orexin Antagonism as a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use Disorder
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
Summary of Study Protocol. This project is designed to test neurobehavioral mechanisms
underlying effects of the dual orexin-1/2 receptor antagonist suvorexant on sleep efficiency
and opioid abstinence, and whether these outcomes are independent of one another. This will
be the first study to investigate whether suvorexant improves outpatient opioid abstinence
and sleep efficiency; and whether improving sleep mediates the improved opioid abstinence
outcome. 180 participants with opioid use disorder (OUD) who have just completed
detoxification will complete this intent-to-treat study.